Figure 1From: Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504) Per patient mean cost in Arm A (erlotinib followed by docetaxel and gemcitabine (DG) and Arm B (DG followed by erlotinib). Back to article page